Država: Velika Britanija
Jezik: engleski
Izvor: VMD (Veterinary Medicines Directorate)
Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
MSD Animal Health UK Limited
QI06AD04
Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Lyophilisate and solvent for suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Cats
Live Viral Vaccine
Authorized
2007-05-01
Revised: February 2023 AN: 00709/2022 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Tricat Trio, lyophilisate and solvent for suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (1 ml) of reconstituted vaccine contains: ACTIVE SUBSTANCES: Live attenuated feline calicivirus, strain F9: 10 4.6 PFU 1 ; Live attenuated feline rhinotracheitis virus, strain G2620A: 10 5.2 PFU 1 ; Live attenuated feline panleucopenia virus, strain MW-1: 10 4.3 CCID 50 2 . 1 PFU: Plaque-Forming Units 2 CCID 50 : Cell Culture Infectious Dose 50% EXCIPIENTS: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. Lyophilisate: off-white pellet. Solvent: clear colourless solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of cats: - to reduce the clinical signs caused by infection with feline calicivirus (FCV) and rhinotracheitis virus (FVR), - to prevent the clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPLV). Onset of immunity: for FCV and FVR: 4 weeks; for FPLV: 3 weeks. Duration of immunity for FCV and FVR: 1 year, for FPLV: 3 years. 4.3 CONTRAINDICATIONS See section 4.7 Revised: February 2023 AN: 00709/2022 Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccinate healthy animals only. Maternal antibodies, which may persist up to the age of 9-12 weeks, can have a negative influence on the efficacy of vaccination. In the presence of maternal antibodies, vaccination may not completely prevent the clinical signs, leucopenia and virus excretion following an FPLV infection. In such cases where a relatively high level of maternally derived antibodies is expected, the vaccination schedule should be planned accordingly. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals: Not applicable. Special precautions to be Pročitajte cijeli dokument